- DepoTech has begun the filing of its New Drug Application with the US Food and Drug Administration for its anticancer agent DepoCyt (sustained-release cytarabine) for patients with neoplastic meningitis arising from solid tumors. In a pivotal Phase III trial, DepoCyt demonstrated a higher complete response rate, a higher median survial and a longer time to disease progression compared to methotrexate (Marketletter October 28). In alliance with Chiron, Phase III trials will continue, with a Phase IV trial also underway in the USA and Canada. Chiron is conducting trials in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze